首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Hodgkin lymphoma among US solid organ transplant recipients.
【24h】

Hodgkin lymphoma among US solid organ transplant recipients.

机译:美国实体器官移植受者中的霍奇金淋巴瘤。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: To assess the risk and identify risk factors of Hodgkin lymphoma (HL) in solid organ transplant recipients. Prior research has been limited by the rarity of HL and the requirement for extended follow-up after transplantation. METHODS: Using data from the Scientific Registry of Transplant Recipients (SRTR), we conducted a retrospective cohort study of US solid organ transplant recipients (1997-2007). We estimated hazard ratios (HRs) for HL risk factors using proportional hazards regression. Standardized incidence ratios (SIRs) compared HL risk in the transplant cohort with the general population. RESULTS: The cohort included 283,190 transplant recipients (average follow-up: 3.7 years after transplantation). Based on 73 cases, HL risk factors included male gender (HR: 2.1, 95% CI: 1.2-3.7), young age (4.0, 2.3-6.8), and Epstein-Barr virus (EBV) seronegativity at the time of transplantation (3.1, 1.2-8.1). Among tumors with EBV status information, 79% were EBV positive, including all tumors in recipients who were initially seronegative. Overall, HL risk was higher than in the general population (SIR: 2.2) and increased monotonically over time after transplantation (SIR: 4.1 at 8-10 years posttransplant). Excess HL risk was especially high after heart and/or lung transplantation (SIR: 3.2). CONCLUSION: HL is a late complication of solid organ transplantation. The high HL risk in recipients who were young or EBV seronegative at the time of transplant and the fact that most HL tumors were EBV positive highlight the role of primary EBV infection and poor immune control of this virus. The occurrence of HL may rise with improved long-term survival in transplant recipients.
机译:背景:评估实体器官移植受者的霍奇金淋巴瘤(HL)的风险并确定其危险因素。 HL的罕见性以及移植后需要延长随访的时间限制了先前的研究。方法:使用来自移植接受者科学注册处(SRTR)的数据,我们对美国实体器官移植接受者进行了一项回顾性队列研究(1997-2007年)。我们使用比例风险回归估算了HL危险因素的危险比(HRs)。标准化发生率(SIR)将移植队列中的HL风险与普通人群进行了比较。结果:该队列包括283190名移植接受者(平均随访:移植后3。7年)。基于73例病例,HL危险因素包括男性(HR:2.1,95%CI:1.2-3.7),年轻(4.0,2.3-6.8)和移植时的爱泼斯坦-巴尔病毒(EBV)血清阴性( 3.1,1.2-8.1)。在具有EBV状态信息的肿瘤中,有79%的EBV阳性,包括最初血清反应阴性的受体中的所有肿瘤。总体而言,HL风险高于一般人群(SIR:2.2),并且随移植时间的推移单调增加(SIR:移植后8-10年时为4.1)。在心脏和/或肺移植后,过量的HL风险尤其高(SIR:3.2)。结论:HL是实体器官移植的晚期并发症。移植时年轻或EBV血清阴性的受体中高HL风险以及大多数HL肿瘤为EBV阳性的事实突出了原发性EBV感染的作用以及对该病毒的免疫控制差。 HL的发生可能随着移植受者的长期生存改善而上升。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号